Clinical trials: Aripiprazole, completed
Tourette's Disorder
ABF Tourette's Disorder Post Marketing Surveillance Study
This is a Post-Marketing Surveillance study of Abilify® tablets in accordance with Korean regulations on New Drug Re-examination (i.e. New Drug Re-examination Standards: KFDA Notification No. 2010-94 dated 27 December 2010).
- Trial name
- NCT01795105
- Where
- 4 sites in South Korea
- Volunteers
- 692 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Healthy Male Adults
Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults
To investigate the bioequivalence of aripiprazole between administration of one ASC-01 tablet (aripiprazole 3 mg/sertraline 100 mg combination drug) and concomitant administration of one aripiprazole 3-mg tablet and two…
- Trial name
- NCT03342963
- Testing
- ASC-01, Aripiprazole and sertraline
- Where
- Japan
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of various doses and dosing intervals of aripiprazole lauroxil.
- Trial name
- NCT02320032
- Testing
- Aripiprazole Lauroxil
- Where
- 16 sites in United States
- Volunteers
- 140 people
- Sponsor
- Alkermes, Inc.
Bipolar Disorder I
Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)
To investigate the safety for an observation period of 52 weeks with use of Abilify prolonged release aqueous suspension for intramuscular (IM) injection in patients with bipolar I disorder for prevention of recurrence/relapse of…
- Trial name
- NCT04812379
- Testing
- Abilify prolonged release aqueous suspension for IM injection (Aripiprazole)
- Where
- Japan
- Volunteers
- 535 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder
This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive…
- Trial name
- NCT00095823
- Testing
- Antidepressant + Aripiprazole
- Where
- 20 sites in United States
- Volunteers
- 1,200 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Postpartum Depression
Aripiprazole and Resistant Postpartum Depression
Currently there are no controlled data on the management of postpartum depression that fails to respond to adequate antidepressant therapy.
- Trial name
- NCT01386086
- Testing
- aripiprazole
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Diabetes
Examining the Effects of Antipsychotic Medications on Insulin Sensitivity
This study will examine the effects of two different antipsychotic medications on control of blood sugar in people who are at risk of diabetes but mentally healthy.
- Trial name
- NCT00895921
- Testing
- Olanzapine, Aripiprazole
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation
Schizophrenia
Aripiprazole IM Depot for Chinese Patients With Schizophrenia
This study assess pharmacokinetics and safety of single-administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg in patients with schizophrenia.
- Trial name
- NCT03287505
- Testing
- Aripiprazole IM Depot
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Otsuka Beijing Research Institute
Schizophrenia OCD, Obsessive Compulsive Disorder
Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)
To evaluate the effectiveness of flexible doses (15-30mg) of Aripiprazole in the treatment of patients with schizophrenia and co-morbid symptoms of OCD in the outpatient setting.
- Trial name
- NCT00374348
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Jamaica Hospital Medical Center
Schizophrenia, Psychotic Disorders
A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to investigate whether a long-acting injectable formulation of risperidone provides better effectiveness over 2 years, as measured by the time to relapse, compared with quetiapine tablets in a routine…
- Trial name
- NCT00216476
- Testing
- Aripiprazole, Risperidone Long Acting Injectable (LAI), Quetiapine
- Where
- 96 sites in Austria, Bulgaria and 22 more
- Volunteers
- 753 people
- Sponsor
- Janssen-Cilag International NV
Bipolar Disorder
Aripiprazole in Late Life Bipolar Disorder
The purpose of this research study is to analyze the effectiveness and tolerability of a new medication, aripiprazole (Abilify), in individuals age 50 years and older who have bipolar disorder (manic-depressive illness).
- Trial name
- NCT00194038
- Testing
- Aripiprazole
- Volunteers
- 20 people
- Sponsor
- University Hospitals Cleveland Medical Center
Major Depressive Disorder
A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder
This trial is a 52-week safety study to evaluate the safety of adjunctive aripiprazole in outpatients with major depressive disorder who have experienced an incomplete response to an ongoing antidepressant trial.
- Trial name
- NCT00095745
- Testing
- Antidepressant + Aripiprazole
- Where
- 58 sites in United States
- Volunteers
- 1,002 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Gambling Disorder, Psychotic Disorders
Prospective Multicenter Cohort Study Evaluating the Incidence and Risk Factors for Problem Gambling Among Young Adults With First-episode Psychosis
The aims of this propsective cohort study are to get a better understanding of the association between problem gambling and psychotic disorders among young adults with first-episode psychosis.
- Trial name
- ANTE-UP (NCT05686772)
- Testing
- Antipsychotic use, Psychiatric comorbidities, Sociodemographics/socioeconomic status
- Where
- 2 sites in Canada
- Volunteers
- 520 people
- Sponsor
- Laval University
Schizophrenia
Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia
This study design is subject to relevant SFDA regulations about clinical trials. Patients will be screened for inclusion into the study at the initial visit(240 patients to be recruited) and then undergo a minimum of 3-7 day's…
- Trial name
- NCT00202007
- Testing
- Aripiprazole tablet, 5-30mg/day, oral, 6 weeks, Risperidone tablet, 1-6mg/day, oral, 6 weeks
- Where
- 6 sites in China
- Volunteers
- 240 people
- Sponsor
- Otsuka Beijing Research Institute
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development
Healthy Subjects
Bioequivalence Study of Aripiprazole in Healthy Adult Subjects Under Fasting Condition
To evaluate and compare the relative plasma bioavailability and therefore the bioequivalence of two different immediate release products each containing Aripiprazole 10 mg, after administering a single oral dose, to healthy adult…
- Trial name
- NCT05532254
- Testing
- Aripiprazole 10 mg tablet, Abilify® 10 mg tablet
- Where
- Egypt
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Future University in Egypt
Normal Volunteers
Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer
The aim of the study is to investigate the negative symptoms and cognitive function after administration of antipsychotics in healthy volunteer.
- Trial name
- NCT01185418
- Testing
- risperidone, aripiprazole, haloperidol
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Schizophrenia
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.
- Trial name
- NCT01052103
- Testing
- LY2140023, Standard of Care
- Where
- 9 sites in United States, Israel and 2 more
- Volunteers
- 167 people
- Sponsor
- Denovo Biopharma LLC
Overweight, Hyperlipidemia
The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia
This is a 2-year study proposing to examine the effects of aripiprazole on heart health factors such as serum lipids, serum leptin, fasting blood sugar, body weight and blood pressure.
- Conditions
- Overweight, Hyperlipidemia, Cardiovascular Diseases
- Trial name
- NCT00222833
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pittsburgh
Substance Abuse, HIV Infections
Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals
Studies demonstrate that methamphetamine (meth) use is associated with high-risk sexual behavior among men who have sex with men (MSM), putting meth-using MSM at extraordinarily high risk for transmitting or acquiring HIV.
- Trial name
- NCT00497055
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- San Francisco Department of Public Health